



available at www.sciencedirect.com

journal homepage: euoncology.europeanurology.com



European Association of Urology

Editorial by M.-P. St Laurent et al. on pp. 222–223 of this issue

Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum

Irene J. Beijert^{a,b}, Anouk E. Hentschel^{a,b}, Johannes Bründl^c, Eva M. Compérat^{d,e}, Karin Plass^f, Oscar Rodríguez^g, Jose D. Subiela Henríquez^g, Virginia Hernández^{d,h}, Enrique de la Peña^h, Isabel Alemanyⁱ, Diana Turturica^j, Francesca Pisano^{g,j}, Francesco Soria^j, Otakar Čapoun^{d,k}, Lenka Bauerová^l, Michael Pešl^k, H. Maxim Bruins^{d,m}, Willemien Runneboomⁿ, Sonja Herdegen^c, Johannes Breyer^c, Antonin Brisuda^o, Ana Calatrava^p, José Rubio-Briones^q, Maximilian Seles^r, Sebastian Mannweiler^s, Judith Bosschieter^b, Venkata R.M. Kusuma^t, David Ashabere^t, Nicolai Huebner^u, Juliette Cotte^v, Laura S. Mertens^a, Francesco Claps^a, Alexandra Masson-Lecomte^d, Fredrik Liedberg^d, Daniel Cohen^{d,w}, Luca Lunelli^x, Olivier Cussenot^x, Soha El Sheikh^y, Dimitrios Volanis^w, Jean-François Côté^z, Morgan Rouprêt^{d,v}, Andrea Haitel^{aa}, Shahrokh F. Shariat^{d,o,u}, A. Hugh Mostafid^{d,t}, Jakko A. Nieuwenhuijzen^b, Richard Zigeuner^{d,r}, Jose L. Dominguez-Escrig^{d,p}, Jaromir Hacek^{bb}, Alexandre R. Zlotta^{cc}, Maximilian Burger^{c,d}, Matthias Evert^{dd}, Christina A. Hulsbergen-van de Kaaⁿ, Antoine G. van der Heijden^m, Lambertus A.L.M. Kiemeny^{ee}, Viktor Soukup^{d,k}, Luca Molinaro^{ff}, Paolo Gontero^{d,j}, Carlos Llorente^h, Ferran Algaba^{gg}, Joan Palou^{d,g}, James N'Dow^f, Maria J. Ribal^f, Theo H. van der Kwast^{hh}, Marko Babjuk^{d,o,u}, Richard J. Sylvester^{d,i}, Bas.W.G. van Rhijn^{a,c,d,cc,*;†}

^a Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ^b Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands; ^c Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; ^d European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; ^e Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France; ^f European Association of Urology Guidelines Office, Arnhem, The Netherlands; ^g Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; ^h Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain; ⁱ Department of Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain; ^j Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy; ^k Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; ^l Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; ^m Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands; ⁿ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands; ^o Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; ^p Department of Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain; ^q Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain; ^r Department of Urology, Medical University of Graz, Graz, Austria; ^s Department of Pathology, Medical University of Graz, Graz, Austria; ^t Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK; ^u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria; ^v Department of Urology, Pitié Salpêtrière Hospital, AP-HP, GRC n°5, ONCOTYPE-URO, Sorbonne University, Paris, France; ^w Department of Urology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK; ^x Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France; ^y Department of Pathology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK; ^z Department of Pathology, Pitié Salpêtrière Hospital, AP-HP, Pierre et Marie Curie Medical

[†] These authors share senior authorship.

* Corresponding author. Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel. +31 20 5122553.

E-mail address: b.v.rhijn@nki.nl (Bas.W.G. van Rhijn).

<https://doi.org/10.1016/j.euo.2023.01.004>

2588-9311/© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

School, Sorbonne University, Paris, France; ^{aa} Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria; ^{bb} Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; ^{cc} Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada; ^{dd} Department of Pathology, University of Regensburg, Regensburg, Germany; ^{ee} Department of Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands; ^{ff} Department of Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy; ^{gg} Department of Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; ^{hh} Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada

Article info

Article history:

Received 23 August 2022

Received in Revised form

5 December 2022

Accepted 2 January 2023

Available online 18 January 2023

Associate Editor:

Ashish M. Kamat

Statistical Editor:

Andrew Vickers

Keywords:

Bladder

Cancer

Carcinomas

Grade

G3

Non-muscle-invasive

Stage Ta

Urothelial

World Health Organization

Abstract

Background: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive.

Objective: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas.

Design, setting, and participants: Individual patient data for 5170 primary Ta–T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018.

Outcome measurements and statistical analysis: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution.

Results and limitations: Ta G3 represented 7.5% (387/5170) of Ta–T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 ($p = 0.9$) or T1 G3 ($p = 0.4$). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7–4.8%) of Ta G2, 13% (95% CI 9.3–17%) of Ta G3, and 20% (95% CI 17–23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 ($p < 0.001$) and longer than for T1 G3 ($p = 0.002$). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS ($p = 0.5$). Multivariable analyses for recurrence and progression showed similar results.

Conclusions: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis that is comparable to that of T1 G3 with CIS. Our results support the recent EAU NMIBC guideline changes for more refined risk stratification of Ta G3 tumors because many of these patients have better prognosis than previously thought.

Patient summary: We used data from 17 centers in Europe and Canada to assess the prognosis for patients with stage Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC). Time to cancer progression for Ta G3 cancer differed from both Ta G2 and T1 G3 tumors. Our results support the recent change in the European Association of Urology guidelines for more refined risk stratification of Ta G3 NMIBC because many patients with this tumor have better prognosis than previously thought.

© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease, which is reflected in differences in recurrence and progression [1,2]. To determine the optimal treatment and surveillance for each tumor, it is important to know where the tumor lies in the spectrum of recurrence and progression. Clinical and pathological information can help to predict the risks of recurrence and progression. The main prognosticators for recurrence are tumor multiplicity, tumor size, and prior recurrence [2]. Tumor stage and histological grade are important prognostic factors for

progression [1,2]. As grade correlates with stage, the majority of Ta carcinomas are of lower grade, whereas the majority of T1 carcinomas are of higher grade. Therefore, Ta grade 3 (G3) tumors are relatively rare and estimated to represent approximately 7% of all Ta carcinomas [3]. Although the noninvasive character (Ta component) suggests limited aggressiveness, the G3 morphology might indicate high risk of progression. Therefore, the interpretation of G3 disease confined to the urothelium is ambiguous: should it be considered as a relatively indolent disease with lower risk of progression or as an aggressive undifferentiated carcinoma? Some studies suggest that Ta G3 carcinomas are potentially

† These authors share senior authorship.

as lethal as T1 carcinomas, while others suggest that Ta G3 carcinomas should not be considered as aggressive as T1 G3 carcinomas [3–5]. Notably, guidelines have changed their recommendations on the management of Ta G3 carcinomas over the years. According to the previous 2020 European Association of Urology (EAU) NMIBC guidelines, all Ta G3 carcinomas were classified as high risk and should be managed as T1 carcinomas [6]. However, in the 2021 EAU NMIBC guidelines, Ta G3 tumors can either be intermediate, high, or very high risk, depending on the presence of carcinoma in situ (CIS), the patient's age, and tumor size and multiplicity [7].

Since pathological diagnosis of a Ta G3 tumor is rather unusual, evaluation of the prognosis for patients with Ta G3 tumors is complicated. Moreover, assessment of the risk of progression in patients with Ta G3 is not straightforward because of differences in the presence of concomitant CIS, adjuvant treatment modalities, and follow-up duration. In the current study, we aimed to evaluate the prognosis of primary Ta G3 carcinomas, with or without CIS and/or Bacillus Calmette-Guérin (BCG) treatment, in comparison to primary Ta G2 and primary T1 G3 carcinomas within a large cohort of patients with Ta–T1 disease.

2. Patients and methods

2.1. Patients, treatment, and follow-up

In this multicenter study, we retrospectively identified 5295 patients with primary Ta–T1 NMIBC from 17 hospitals with their first diagnosis between 1990 and 2018. During quality control, we excluded 125 cases (2%) because of duplicate entries, <3 months of follow-up, missing grade or stage, CIS-only, muscle-invasive tumor at repeat transurethral resection of bladder tumor (TURBT), or death, progression, or cystectomy within 3 months [8]. Decisions on treatment, such as re-TURBT and/or adjuvant bladder instil-

lations, and follow-up were made by the treating clinician. Patients were followed for both their first recurrence and progression. Tumor recurrence was defined as a pathologically confirmed Ta–T1 bladder tumor during follow-up [1,2]. Tumor progression was defined as the development of muscle-invasive and/or metastatic disease [1,2].

2.2. Statistical analysis

Descriptive statistics were summarized as the frequency and percentage for categorical data with 95% confidence intervals (CIs) and as the median and interquartile range (IQR) for continuous data. With the date of the primary TURBT as the starting point, time to recurrence and time to progression were estimated using cumulative incidence functions with death prior to an event as a competing risk. Patients with no events were censored at their date of last follow-up. Times to recurrence and progression were compared using a log-rank test stratified by institution. The curves were curtailed at 15 yr of follow-up.

Multivariable Cox proportional-hazard models for recurrence and progression stratified by institution were used to compare the prognosis between World Health Organization (WHO) 1973 grade categories in combination with stage, adjusting for sex (female vs male), age (≤ 70 yr vs > 70 yr), tumor multiplicity (solitary vs multiple), tumor size (< 3 cm vs ≥ 3 cm), presence of CIS (no vs yes), single instillation of intravesical chemotherapy (no vs yes), intravesical chemotherapy induction (no vs yes), BCG induction (no vs yes), and re-TURBT (no vs yes). Terms were added to the Cox model to assess interaction between stage/grade categories and CIS. The heterogeneity of prognosis according to the presence of CIS was tested using Cochran's Q statistic and illustrated in a forest plot. Statistical analyses were performed using SPSS v26.0 (IBM, Armonk, NY, USA) and Stata v14.1 (StataCorp, College Station, TX, USA). Tests were two-sided and p values < 0.05 were considered statistically significant.

Table 1 – Patient and tumor characteristics and treatment for every stage and grade combination among the 5170 patients with Ta–T1 primary bladder cancer included in the study

	Ta G1 (n = 1121)	Ta G2 (n = 1803)	Ta G3 (n = 387)	T1 G1 (n = 99)	T1 G2 (n = 734)	T1 G3 (n = 1026)
Median age, yr (IQR)	66 (58–75)	68 (61–76)	71 (63–78)	68 (61–75)	69 (61–77)	70 (63–78)
Multiple tumors, n (%)	284 (25)	569 (32)	178 (46)	35 (35)	273 (37)	431 (42)
Data missing	6	12	4	0	4	7
Tumor size ≥ 3 cm, n (%)	223 (20)	419 (23)	128 (33)	30 (30)	334 (46)	451 (44)
Data missing	47	114	39	2	40	56
Concomitant CIS, n (%)	10 (0.9)	63 (3.5)	79 (20)	1 (1.0)	57 (7.7)	265 (26)
Single instillation, n (%)	502 (45)	742 (41)	127 (33)	56 (57)	228 (31)	232 (23)
Data missing	105	153	54	1	57	142
Induction CTx, n (%)	136 (12)	315 (17)	57 (15)	11 (11)	121 (16)	78 (7.6)
Data missing	8	11	1	1	3	6
BCG induction, n (%)	26 (2.3)	238 (13)	220 (57)	2 (2.0)	302 (41)	748 (73)
Data missing	8	21	2	0	2	6
Re-TURBT, n (%)	64 (5.7)	235 (13)	137 (35)	9 (9.0)	266 (36)	624 (61)
Data missing	82	73	8	0	71	80
Prognostic risk group, n (%) ^a						
Low risk	893 (80)	0 (0)	0 (0)	31 (31)	0 (0)	0 (0)
Intermediate risk	218 (19)	1677 (93)	164 (42)	59 (60)	133 (18)	0 (0)
High risk	10 (0.9)	126 (7)	209 (54)	9 (9.1)	581 (79)	723 (70)
Very high risk	0 (0)	0 (0)	14 (3.6)	0 (0)	20 (2.7)	303 (30)

G = tumor grade according to the World Health Organization 1973 grading system; IQR = interquartile range; CIS = carcinoma in situ; CTx = chemotherapy; BCG = Bacillus Calmette-Guérin; Re-TURBT = repeat transurethral resection of bladder tumor.

^a European Association of Urology 2021 prognostic risk factor groups for non-muscle-invasive bladder cancer [1,7].

3. Results

Baseline patient and tumor characteristics and treatment data for 5170 patients with primary Ta–T1 bladder cancer from 17 hospitals are presented in Table 1. Median follow-up for patients without recurrence or progression was 46.9 mo (IQR 23.2–84.9). A total of 387 patients with Ta G3 carcinomas were identified, corresponding to 7.5% of Ta–T1 tumors and 12% of Ta tumors. All 17 participating hospitals diagnosed Ta G3 tumor(s) during the study period. Recurrence was observed in 2239 patients and stage progression in 387 patients.

3.1. Prognosis of Ta G3 compared to Ta G2 and T1 G3 carcinomas

3.1.1. Time to recurrence

The recurrence risk at 1 yr was 23% (95% CI 18–27%) for Ta G3, 19% (95% CI 17–20%) for Ta G2, and 28% (95% CI 25–31%) for T1 G3 carcinomas. Recurrence at 5 yr was 47% (95% CI 41–52%) for Ta G3, 48% (95% CI 45–51%) for Ta G2, and 48% (95% CI 44–51%) for T1 G3 carcinomas.

Time to recurrence did not significantly differ between Ta G3 and Ta G2 ($p = 0.9$) or Ta G3 and T1 G3 ($p = 0.4$). Figure 1 shows the cumulative risk of recurrence for Ta G2, Ta G3, and T1 G3 carcinomas over time. On multivariable analysis, time to recurrence did not significantly differ between Ta G3 and Ta G2 carcinomas (hazard ratio [HR] 0.98, 95% CI 0.78–1.23; $p = 0.9$) or between Ta G3 and T1 G3 carcinomas (HR 1.06, 95% CI 0.85–1.34; $p = 0.6$; Table 2).

3.1.2. Time to progression

The risk of progression at 1 yr of follow-up was 0.4% (95% CI 0.2–0.8%) for Ta G2, 2.5% (95% CI 1.2–4.5%) for Ta G3, and 7.2% (95% CI 5.7–8.9%) for T1 G3. At 5 yr, the risk of progression was 3.6% (95% CI 2.7–4.8%) for Ta G2, 13% (95% CI 9.3–17%) for Ta G3, and 20% (95% CI 17–23%) for T1 G3 tumors.

Time to progression significantly differed between Ta G2 and Ta G3 ($p < 0.001$) and between Ta G3 and T1 G3 ($p = 0.002$). Figure 2 shows the cumulative risk of progression for Ta G2, Ta G3 and T1 G3 carcinomas over time. On

Table 2 – Multivariable analysis of factors affecting time to recurrence for Ta G2, Ta G3, and T1 G3 carcinomas stratified by institution^a

	HR (95% CI)	p value
Age (<70 yr vs >70 yr)	1.18 (1.05–1.35)	0.008
Sex (female vs male)	0.96 (0.82–1.13)	0.6
Tumor multiplicity (solitary vs multiple)	1.72 (1.51–1.96)	<0.001
Tumor size (<3 cm vs ≥3 cm)	1.35 (1.18–1.56)	<0.001
Presence of CIS (no vs yes)	1.18 (0.95–1.46)	0.1
Single instillation (no vs yes)	0.76 (0.63–0.91)	0.003
Induction chemotherapy (no vs yes)	0.76 (0.62–0.92)	0.006
Induction BCG (no vs yes)	0.65 (0.55–0.78)	<0.001
Re-TURBT (no vs yes)	0.98 (0.82–1.18)	0.9
Ta G3 versus Ta G2	0.98 (0.78–1.23)	0.9
Ta G3 versus T1 G3	1.06 (0.85–1.34)	0.6

HR = hazard ratio; CI = confidence interval; CIS = carcinoma in situ; Re-TURBT = repeat transurethral resection of bladder tumor; BCG = Bacillus Calmette–Guérin; G = tumor grade according to the World Health Organization 1973 grading system.

^a Recurrence did not significantly differ for Ta G3 versus Ta G2 or Ta G3 versus T1 G3 carcinomas.

multivariable analysis, time to progression was significantly shorter for Ta G3 versus Ta G2 (HR 0.31, 95% CI 0.18–0.52; $p < 0.001$) and longer for Ta G3 versus T1 G3 (HR 1.69, 95% CI 1.09–2.6; $p = 0.018$; Table 3).

3.1.2.1. Time to progression for patients with or without concomitant CIS. In total, 63/1803 (3.5%) of patients with Ta G2 had concomitant CIS versus 79/387 (20%) patients with Ta G3 and 265/1026 (26%) patients with T1 G3 (Table 1). The risk of progression at 5 yr was 5.9% (95% CI 1.5–15%) for Ta G2 with CIS, 20% (95% CI 11–30%) for Ta G3 with CIS, and 22% (95% CI 16–28%) for T1 G3 with CIS. Time to progression significantly differed for Ta G2 and Ta G3 patients with concomitant CIS ($p = 0.004$) but not for Ta G3 and T1 G3 patients with concomitant CIS ($p = 0.8$). Similar results were found on multivariable analysis, with a significant difference for Ta G3 versus Ta G2 (HR 0.10, 95% CI 0.01–0.76; $p = 0.027$) but not between Ta G3 and T1 G3 (HR 1.29, 95% CI 0.58–2.90; $p = 0.5$).

The risk of progression at 5 yr was 3.5% (95% CI 2.6–4.7%) for Ta G2 without CIS, 11% (95% CI 7.2–16%) for Ta G3 with-




Fig. 1 – Cumulative incidence curves for recurrence of Ta G2 (solid green line), Ta G3 (dashed blue line) and T1 G3 (dashed red line) carcinomas. Time to recurrence did not significantly differ between Ta G2 and Ta G3 ($p = 0.9$) or T1 G3 ($p = 0.4$). G = tumor grade according to the World Health Organization 1973 grading system.




Fig. 2 – Cumulative incidence curves for progression of Ta G2 (solid green line), Ta G3 (dashed blue line), and T1 G3 (dashed red line) carcinomas. Time to progression was significantly shorter for Ta G3 in comparison to Ta G2 ($p < 0.001$) and longer in comparison to T1 G3 ($p = 0.002$). G = tumor grade according to the World Health Organization 1973 grading system.

Table 3 – Multivariable analysis of factors affecting time to progression for Ta G2, Ta G3, and T1 G3 carcinomas stratified by institution^a

	HR (95% CI)	p value
Age (<70 yr vs >70 yr)	1.37 (1.01–1.86)	0.043
Sex (female vs male)	0.92 (0.63–1.34)	0.7
Tumor multiplicity (solitary vs multiple)	1.62 (1.19–2.19)	0.002
Tumor size (<3 cm vs ≥3 cm)	1.48 (1.08–2.02)	0.013
Presence of CIS (no vs yes)	1.44 (0.98–2.13)	0.06
Single instillation (no vs yes)	0.70 (0.47–1.04)	0.08
Induction chemotherapy (no vs yes)	0.53 (0.31–0.92)	0.02
Induction BCG (no vs yes)	0.59 (0.41–0.86)	0.006
Re-TURBT (no vs yes)	1.07 (0.74–1.55)	0.7
Ta G3 versus Ta G2	0.31 (0.18–0.52)	<0.001
Ta G3 versus T1 G3	1.69 (1.09–2.60)	0.018

HR = hazard ratio; CI = confidence interval; CIS = carcinoma in situ; Re-TURBT = repeat transurethral resection of bladder tumor; BCG = bacillus Calmette-Guérin; G = tumor grade according to the World Health Organization 1973 grading system.

^a Time to progression differed significantly for Ta G3 versus Ta G2 and Ta G3 versus T1 G3 carcinomas.

out CIS, and 19% (95% CI 16–23%) for T1 G3 without CIS. Among patients without concomitant CIS, time to progression was significantly shorter for Ta G3 than for Ta G2 ($p = 0.007$) and longer for Ta G3 than for T1 G3 ($p < 0.001$) carcinomas.

The results of the subgroup analysis were confirmed by a significant interaction in the Cox model between time to progression for Ta G3 and T1 G3 according to the presence of concomitant CIS ($p = 0.037$ for Cochran's Q; [Supplementary Fig. 1](#)).

3.1.2.2. Time to progression for patients with or without BCG induction. BCG induction therapy was given to 238/1803 (13%) patients with Ta G2 carcinomas, in comparison to 220/387 (57%) patients with Ta G3 and 748/1026 (73%) patients with T1 G3 carcinomas ([Table 1](#)). Stratified by the 2021 EAU NMIBC risk groups, 79/164 (48%) patients with intermediate-risk Ta G3 received BCG, versus 141/223 (63%) patients with high-/very high-risk Ta G3. In the group receiving BCG induction, the risk of progression at 5 yr was 7.4% (95% CI 4.0–12%) for Ta G2, 15% (95% CI 9.8–21%) for Ta G3, and 19% (95% CI 16–22%) for T1 G3. There was a signif-

icant difference in time to progression for patients who received BCG induction between Ta G2 and Ta G3 ($p = 0.002$). However, time to progression was not significantly different between Ta G3 and T1 G3 ($p = 0.17$). Similar results were found on multivariable analysis, with a significant difference between Ta G3 and Ta G2 (HR 0.24, 95% CI 0.09–0.61; $p = 0.003$) but not between Ta G3 and T1 G3 carcinomas (HR 1.50, 95% CI 0.89–2.53; $p = 0.13$).

In the group that did not receive BCG induction, the risk of progression at 5 yr was 3.0% (95% CI 2.1–4.2%) for Ta G2, 10% (95% CI 5.8–17%) for Ta G3, and 22% (95% CI 17–28%) for T1 G3. Time to progression for patients without BCG induction was significantly shorter for Ta G3 than for Ta G2 ($p = 0.007$) and longer than for T1 G3 ($p < 0.001$).

3.1.3. Time to progression for Ta G3 carcinomas by EAU NMIBC risk group

According to the risk groups in the 2021 EAU NMIBC guideline, 42% of Ta G3 tumors in the present study were considered intermediate risk, 54% were high risk, and 3.6% very high risk ([Table 1](#)), as opposed to the previous EAU NMIBC guideline, according to which all Ta G3 tumors were high risk by definition. Time to progression ([Fig. 3](#)) significantly differed between intermediate-risk Ta G3 and high-risk/very high-risk Ta G3 ($p = 0.023$).

4. Discussion

Patients with Ta G3 carcinomas represent a small group within the NMIBC spectrum. The literature on oncological outcomes and prognostic factors for these patients is sparse and results are inconclusive or contradictory, probably because of the rarity of Ta G3 carcinomas, as well as differences in patient and/or tumor characteristics, treatment modalities, and follow-up duration. In our study we retrospectively identified 387 Ta G3 tumors, corresponding to 7.5% of 5170 Ta–T1 carcinomas, which is in line with a previous report [3]. From a clinical point of view, time to recurrence was similar between Ta G3 and Ta G2 and T1 G3 carcinomas. Furthermore, patients with Ta G3 carcinoma




Fig. 3 – Cumulative incidence curves for progression of intermediate-risk Ta G3 ($n = 164$; blue line) and high-risk ($n = 209$)/very high-risk ($n = 14$) Ta G3 (red line) Ta G3 according to European Association of Urology risk groups for non-muscle-invasive bladder cancer. Time to progression significantly differed between the intermediate-risk and high-risk/very high-risk groups ($p = 0.023$). G = tumor grade according to the World Health Organization 1973 grading system.

had a longer time to progression in comparison to those with T1 G3 carcinoma, but a shorter time to progression in comparison to Ta G2. Subgroup analyses showed that patients with Ta G3 NMIBC with concomitant CIS had poorer prognosis and a similar time to progression to patients with T1 G3 with concomitant CIS. Finally, time to progression was significantly longer for intermediate-risk Ta G3 than for high-risk/very high-risk Ta G3.

The aim of grading and staging of bladder cancer is to provide the clinician with an indication of the clinical behavior to tailor treatment and follow-up strategies. Herr [4] reported that Ta G3 carcinomas are potentially as lethal as T1 carcinomas and suggested that aggressive treatment is warranted. However, the study comprised a select subgroup of patients with multiple and recurrent disease. Moreover, 72% had concurrent CIS lesions and all patients received BCG treatment [4]. A review by Sylvester et al. [3] of Ta G3 tumors using data from multiple studies with small numbers of patients found that the risk of progression to muscle-invasive disease was between 20% and 25%. The authors suggested treating and monitoring these patients as high-risk cases [3]. On the contrary, a contemporary larger study of 285 primary Ta G3 carcinomas suggested that Ta G3 without concomitant CIS should not be considered as aggressive as T1 G3 carcinoma [5]. The median follow-up was 44.5 mo and 70% of the patients received BCG induction therapy; no prognostic role for other tumor characteristics such as tumor size and multiplicity in patients with Ta G3 tumors was identified [5]. Our study showed that time to progression of Ta G3 significantly differed from both Ta G2 and T1 G3 carcinomas. Moreover, the distinction is clinically significant since the risk of progression at 5 yr was 3.6% for Ta G2, 13% for Ta G3, and 20% for T1 G3. However, for patients with concomitant CIS, which is regarded as a precursor lesion for the development for invasive disease, even though it is also a mucosa-confined lesion [9], Ta G3 was more like T1 G3 (risk of progression 20% vs 22% at 5 yr). For patients without CIS, Ta G3 had a longer time to progression than T1 G3 (risk of progression 11% vs 19% at 5 yr). It appears that prognosis in terms of progression is not solely based on the G3 or the Ta component and lies more

or less in between the prognosis for each, with the exception of patients with concomitant CIS.

The risk of progression can be mitigated by differences in adjuvant treatment decisions, and it is known that adjuvant BCG treatment reduces the risk of progression [10]. Le Bret et al. [11] suggested that the distinction between Ta and T1 tumors was irrelevant for patients with G3 disease treated with BCG because 25% (8/32) of patients in their series with Ta G3 tumors experienced progression. Comparable results were found in a more recent study with similar risks of progression for patients with primary high-grade (HG/G2–G3) Ta tumors (12/48, 25%) and T1 HG tumors (22/143, 23%) treated with BCG over median follow-up of 55.6 mo [12]. Concomitant CIS was observed in 14% of Ta HG tumors versus 19% of T1 HG tumors [12]. Our subgroup analyses also showed that if patients received BCG induction therapy, time to progression for Ta G3 was more similar to time to progression for T1 G3. The risk of progression at 5 yr was 15% for Ta G3 and 19% for T1 G3 after at least BCG induction. The higher proportion of patients with T1 G3 carcinomas who received BCG treatment (73% of T1 G3 vs 57% of Ta G3 cases) may explain these findings, as more T1 G3 carcinoma patients than Ta G3 patients may have a lower risk of progression. Another possible explanation is that patients with Ta G3 disease with more aggressive characteristics (such as concomitant CIS or larger tumors) were more likely to receive BCG, thereby inducing a selection bias. The likelihood of a selection bias when evaluating a BCG cohort—in ours and previous studies—is supported by the fact that 48% of patients with intermediate-risk Ta G3 received BCG induction, as opposed to 63% of patients with high-/very high-risk Ta G3. Among patients who did not receive BCG induction, Ta G3 was not as aggressive as T1 G3, since the risk of progression at 5 yr was 10% for Ta G3 and 22% for T1 G3.

According to the 2021 EAU NMIBC guideline changes, Ta G3 tumors can be intermediate, high, or very high risk, depending on the presence of CIS, age, and tumor size and multiplicity [7]. Our results support this more refined risk stratification of Ta G3 tumors because many of these patients were no longer classified as high risk but as inter-

mediate risk (42% of Ta G3 cases in our study) with significantly better prognosis than previously thought. In addition, we found that age as well as tumor size and multiplicity were significant prognosticators for progression. Interestingly, Bree et al. [13] advocated the opposite and suggested that all Ta HG tumors, regardless of the new EAU risk stratification, should be considered high risk because of similar risk of progression. However, they analyzed a subset of patients who received BCG, used only the WHO 2004 grading classification, excluded patients with concomitant CIS, and did not compare Ta HG with T1 HG.

Limitations of our study are the retrospective setting, in which differences in adjuvant treatment decisions could influence outcome. The criteria for BCG induction therapy were based on physician discretion and were probably not uniform, with changes in guidelines over the years another factor. Although we applied interaction terms in the Cox model, the subgroup analyses for CIS and induction BCG were still based on relatively small patient numbers. Moreover, while there is some evidence that re-TURBT in high-grade T1 disease may improve prognosis, its value for high-grade Ta disease is inconclusive [14–17]. In our study, re-TURBT was performed in 35% of Ta G3 and 61% of T1 G3 cases. Even though the benefit of re-TURBT is not crystal clear, it is possible that differences in the proportion of patients who underwent re-TURBT may have influenced the results. To overcome the above limitations, our results need prospective validation. Another limitation is the absence of central pathology review. Incorrect staging and grading can result in misclassification of Ta G3 tumors [18,19]. However, this is also true for daily clinical practice, since observer variability is a recognized and inevitable problem in the grading and staging of bladder tumors. A further limitation may be that the WHO 1973 grading system appears to be outdated and is used less frequently than the WHO 2004/2016 system. However, the EAU NMIBC guidelines still advise use of both the WHO 1973 and WHO 2004/2016 grading systems as they both provide prognostic value [1,7,8]. Moreover, we recently showed that the prognostic value of the WHO 1973 system was better for time to progression than the WHO 2004/2016 system and a multidisciplinary opinion paper by the International Society of Urological Pathology advocated the incorporation of WHO 1973 G3 in a future three-tier grading system [8,20]. A strength of our study is the large cohort of patients with primary NMIBC with individual patient data available.

5. Conclusions

Patients with Ta G3 carcinomas represent a small group within the NMIBC spectrum. Our study suggests that Ta G3 carcinomas should be considered as a separate group since time to progression of Ta G3 differed from both Ta G2 and T1 G3 and lay in between these two categories. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis and a similar time to progression as for T1 G3 with CIS. Therefore, our results support the recent EAU NMIBC guideline changes on risk stratification,

in which Ta G3 carcinomas may be classified as intermediate, high, or very high risk, since many of these patients have better prognosis than previously thought.

Author contributions: Irene J. Beijert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Beijert, Sylvester, van Rhijn.

Acquisition of data: Bründl, Compérat, Plass, Rodríguez, Subiela Henríquez, Hernández, de la Peña, Alemany, Turturica, Pisano, Soria, Čapoun, Bauerová, Pešl, Bruins, Runneboom, Herdegen, Breyer, Brisuda, Calatrava, Rubio-Briones, Seles, Mannweiler, Bosschieter, Kusuma, Ashabere, Huebner, Cotte, Mertens, Claps, Masson-Lecomte, Liedberg, Cohen, Lunelli, Cussenot, El Sheikh, Volanis, Côté, Rouprêt, Haitel, Shariat, Mostafid, Nieuwenhuijzen, Zigeuner, Dominguez-Escrig, Hacek, Zlotta, Burger, Evert, Hulsbergen-van de Kaa, van der Heijden, Kiemeny, Soukup, Molinaro, Gontero, Llorente, Algaba, Palou, N'Dow, Ribal, van der Kwast, Babjuk, Sylvester, van Rhijn.

Analysis and interpretation of data: Beijert, Hentschel, Sylvester, van Rhijn.

Drafting of the manuscript: Beijert, Sylvester, van Rhijn.

Critical revision of the manuscript for important intellectual content: Bründl, Compérat, Plass, Rodríguez, Subiela Henríquez, Hernández, de la Peña, Alemany, Turturica, Pisano, Soria, Čapoun, Bauerová, Pešl, Bruins, Runneboom, Herdegen, Breyer, Brisuda, Calatrava, Rubio-Briones, Seles, Mannweiler, Bosschieter, Kusuma, Ashabere, Huebner, Cotte, Mertens, Claps, Masson-Lecomte, Liedberg, Cohen, Lunelli, Cussenot, El Sheikh, Volanis, Côté, Rouprêt, Haitel, Shariat, Mostafid, Nieuwenhuijzen, Zigeuner, Dominguez-Escrig, Hacek, Zlotta, Burger, Evert, Hulsbergen-van de Kaa, van der Heijden, Kiemeny, Soukup, Molinaro, Gontero, Llorente, Algaba, Palou, N'Dow, Ribal, van der Kwast, Babjuk, Sylvester, van Rhijn.

Statistical analysis: Beijert, Sylvester, van Rhijn.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: Sylvester, van Rhijn.

Other: None.

Financial disclosures: Irene J. Beijert certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: None.

Acknowledgments: This study was conducted under the auspices of the EAU NMIBC Guidelines Panel. The EAU Guidelines Office approved the protocol and appropriate ethical approval was obtained at each site. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.euo.2023.01.004>.

References

- [1] Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/

- 2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel. *Eur Urol* 2021;79:480–8.
- [2] Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006;49:466–75.
- [3] Sylvester RJ, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. *Urology* 2005;66(6 Suppl 1):90–107.
- [4] Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. *J Urol* 2000;163:60–1.
- [5] Qahal F, D'Andrea D, Soria F, et al. Primary Ta high grade bladder tumors: Determination of the risk of progression. *Urol Oncol* 2021;39:132.e7–e11.
- [6] Soukup V, Čapoun O, Cohen D, et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. *Eur Urol* 2020;6:479–89.
- [7] Babjuk M, Burger M, Capoun O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). *Eur Urol* 2022;81:75–94.
- [8] van Rhijn BWC, Hentschel AE, Bründl J, et al. Prognostic value of the WHO1973 and WHO2004/2016 classification systems for grade in primary Ta/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel study. *Eur Urol Oncol* 2021;4:182–91.
- [9] Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. *Ther Adv Urol* 2012;4:13–32.
- [10] Sylvester RJ, van der Meijden A, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2002;168:1964–70.
- [11] Lebre T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations. *J Urol* 2000;163:63–7.
- [12] Kilinc MF, Sonmez NC, Dalkilic A, Arisan S, Guney S. Analysis of results of recurrence and progression rates of high-grade Ta bladder cancer and comparison with results of high-grade T1. *Urologia* 2014;81:237–41.
- [13] Bree KK, Hensley PJ, Lobo N, et al. All high-grade Ta tumors should be classified as high risk: bacillus Calmette-Guérin response in high-grade Ta tumors. *J Urol* 2022;208:284–91.
- [14] Holmäng S. High-grade non-muscle-invasive bladder cancer: is re-resection necessary in all patients before intravesical bacillus Calmette-Guérin treatment? *Scand J Urol* 2013;47:363–9.
- [15] Eroglu A, Ekin RG, Koc G, Divrik RT. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. *Int J Clin Oncol* 2020;25:698–704.
- [16] Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/grade 3 bladder cancer treated with bacille Calmette-Guérin. *BJU Int* 2016;118:44–52.
- [17] Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. *Eur Urol* 2018;73:925–33.
- [18] Witjes JA, Kiemeny LA, Schaafsma HE, Debruyn FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. *Br J Urol* 1994;73:172–6.
- [19] Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. *J Urol* 2000;164:1533–7.
- [20] van der Kwast T, Liedberg F, Black PC, et al. International Society of Urological Pathology expert opinion on grading of urothelial carcinoma. *Eur Urol Focus* 2022;8:438–46.